GSK and Vir to seek emergency use clearance for COVID-19 antibody therapy
GlaxoSmithKline and Vir Biotechnology announced that they will immediately request emergency-use authorization in the USA after they finished a late-stage study early, based on the recommendation of an independent monitoring board. VIR-7831 has reduced the number of patients who were hospitalized or died by 85%, compared to placebo.
Antibody treatments are configured to decrease the severity of COVID-19 among patients who were already diagnosed with the infection. Dr. Yael Vidal, who is a board-certified internist advising patients who seek a concierge doctor in Jupiter Florida or in nearby areas, explained to some of her patience the importance of this positive result.
The two companies also said that a new laboratory study showed that the therapy, VIR-7831, was equally effective against the UK variant, the South African variant, and the Brazilian variant of the COVID-19 virus.
This new move brings the antibody therapy for Covid-19 one step closer to becoming yet another weapon against the CoronaVirus pandemic. It joins similar therapies that were introduced by Eli Lilly and Regeneron Pharmaceuticals, receiving recommendations from U.S. and European health regulators earlier.
This antibody treatment was developed under a collaboration between Vir Biotechnology and GlaxoSmithKline, explains Dr. Vidal to patients searching for a concierge physician in Palm Beach Gardens. The fresh recommendation was based on an interim analysis of the data collected from 583 patients, wherein the analysis demonstrated a reduction of 85% in hospitalization or death in the VIR-7831 arm compared to placebo.